Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

KYMR

Kymera Therapeutics Inc

Mar 17 • 04:00PM ET

34.49

Dollar change +0.12
Percentage change 0.35	%

Healthcare • Biotechnology • USA • NASD

Peers: SRRK NRIX ARDX QURE KPTI CRNC RVNC MREO ONCT

| Held by: VTI IWM VB VXF VBK XBI IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.97	Insider Own	16.91%	Shs Outstand	64.89M	Perf Week	4.45%
Market Cap	2.24B	Forward P/E	-	EPS next Y	-4.11	Insider Trans	-0.32%	Shs Float	53.96M	Perf Month	-5.84%
Income	-223.86M	PEG	-	EPS next Q	-0.90	Inst Own	95.08%	Short Float	14.04%	Perf Quarter	-23.38%
Sales	47.07M	P/S	47.59	EPS this Y	-21.97%	Inst Trans	4.85%	Short Ratio	13.06	Perf Half Y	-22.88%
Book/sh	12.88	P/B	2.68	EPS next Y	-13.12%	ROA	-28.81%	Short Interest	7.58M	Perf Year	-18.46%
Cash/sh	7.53	P/C	4.58	EPS next 5Y	-10.17%	ROE	-36.38%	52W Range	29.07 - 53.27	Perf YTD	-14.27%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-26.36%	ROI	-24.59%	52W High	-35.25%	Beta	2.12
Dividend TTM	-	Quick Ratio	7.53	Sales past 5Y	233.20%	Gross Margin	84.34%	52W Low	18.64%	ATR (14)	2.07
Dividend Ex-Date	-	Current Ratio	7.53	EPS Y/Y TTM	-17.79%	Oper. Margin	-545.36%	RSI (14)	48.59	Volatility	5.70% 6.40%
Employees	188	Debt/Eq	0.11	Sales Y/Y TTM	-40.11%	Profit Margin	-475.57%	Recom	1.21	Target Price	58.44
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	-260.29%	Payout	-	Rel Volume	0.65	Prev Close	34.37
Sales Surprise	-48.51%	EPS Surprise	-13.58%	Sales Q/Q	-84.56%	Earnings	Feb 27 BMO	Avg Volume	580.10K	Price	34.49
SMA20	1.79%	SMA50	-7.80%	SMA200	-16.87%	Trades		Volume	374,478	Change	0.35%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55
Dec-02-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$57
Nov-18-24	Initiated	Stephens	Overweight	$65
Sep-09-24	Resumed	Leerink Partners	Outperform	$60
Aug-26-24	Upgrade	Wolfe Research	Peer Perform → Outperform	$65
Apr-22-24	Initiated	Oppenheimer	Outperform	$53
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Jan-04-24	Upgrade	JP Morgan	Neutral → Overweight
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $30
Dec-19-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$26
Jun-30-23	Initiated	Truist	Buy	$50
May-05-23	Upgrade	Raymond James	Mkt Perform → Outperform
Dec-06-22	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $32
Nov-08-22	Initiated	Raymond James	Mkt Perform
Aug-15-22	Initiated	Jefferies	Buy	$40
Aug-03-22	Initiated	Goldman	Buy	$40
Jul-20-22	Initiated	SVB Leerink	Mkt Perform	$26
Apr-28-22	Initiated	Credit Suisse	Outperform	$63

Show Previous Ratings

Feb-28-25 02:15AM	Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
Feb-27-25 08:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -14.45%
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-26-25 07:33AM	What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Feb-20-25 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-30-25 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-15-25 09:38AM	Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last? (Zacks) +8.57%
Jan-14-25 01:28PM	Kymera Therapeutics Surges 10% on Bold 2025 Roadmap to Revolutionize Immunology Treatments (GuruFocus.com) +7.79%
07:00AM	Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-07-25 07:00AM	Kymera Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14 (GlobeNewswire)
Dec-27-24 04:25PM	Leerink sees positive readthrough for Kymera Therapeutics from J&J-Kaken deal (TipRanks)
Nov-26-24 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-05-24 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
03:07AM	Loading…
Nov-01-24 03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
12:04AM	U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners (The Wall Street Journal)
Oct-31-24 08:40AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-30-24 09:10AM	Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-24-24 10:01AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases (GlobeNewswire)
Oct-23-24 07:15AM	Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium (GlobeNewswire)
Oct-09-24 07:00AM	Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Sep-25-24 07:00AM	Kymera Therapeutics Presents Preclinical Data for KT-621, a Potent, Selective, First-In-Class, Oral STAT6 Degrader at the EADV Congress (GlobeNewswire)
Sep-06-24 11:31AM	Why Is Kymera Therapeutics (KYMR) Up 10.9% Since Last Earnings Report? (Zacks)
Aug-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-21-24 11:15AM	Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Aug-20-24 01:02PM	Kymera (KYMR) to Raise $225 Million Through Offering of Shares (Zacks)
07:44AM	Loading…
07:44AM	Avidity, Kymera raise fresh funds; Walgreens partners with BARDA (BioPharma Dive)
Aug-19-24 10:45PM	Kymera Therapeutics Announces Pricing of $225 Million Public Offering (GlobeNewswire)
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
Aug-08-24 09:55AM	Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
Aug-07-24 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-31-24 07:00AM	Kymera Therapeutics to Report Second Quarter 2024 Financial Results on August 7 (GlobeNewswire) +7.17%
Jul-10-24 08:10AM	Kymera Therapeutics (KYMR) Surges 23.4%: Is This an Indication of Further Gains? (Zacks) -8.09%
Jul-09-24 01:30PM	Why Kymera Therapeutics Stock Is Soaring Today (Motley Fool) +23.40%
12:22PM	Kymera Therapeutics soars as Sanofi expands phase 2 trials (Investing.com)
10:44AM	Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug (Investopedia)
09:59AM	Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies (Zacks)
07:00AM	Kymera Therapeutics to Present in Fireside Chat at the UBS Virtual Targeted Protein Degradation Day (GlobeNewswire)
Jul-08-24 04:05PM	Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy (GlobeNewswire) +5.65%
Jun-20-24 08:45AM	Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033 (GlobeNewswire)
Jun-14-24 07:00AM	Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire)
Jun-01-24 08:00AM	Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-29-24 07:00AM	Kymera Therapeutics to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-23-24 05:00PM	Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting (GlobeNewswire)
May-22-24 11:20AM	Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting (GlobeNewswire) -8.52%
May-08-24 07:00AM	Kymera Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-03-24 12:23PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript (Insider Monkey)
09:57AM	Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know (Zacks)
08:44AM	Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 (MT Newswires)
03:19AM	Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:18PM	Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises (MT Newswires)
11:57AM	KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-25-24 10:02AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -5.28%
09:20AM	20 Counties with the Highest Cancer Rates in the US (Insider Monkey)
07:00AM	Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2 (GlobeNewswire)
Apr-08-24 07:00AM	Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting (GlobeNewswire)
Mar-08-24 10:00AM	Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-04-24 11:27PM	Insider Sell: CFO Bruce Jacobs Sells 3,934 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-28-24 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-23-24 11:59AM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-22-24 11:24PM	Q4 2023 Kymera Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
07:35AM	Kymera Therapeutics Inc (KYMR) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-21-24 11:52PM	Director Jeffrey Albers Sells 5,000 Shares of Kymera Therapeutics Inc (KYMR) (GuruFocus.com)
Feb-15-24 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22 (GlobeNewswire)
Feb-10-24 02:56AM	Chief Medical Officer Jared Gollob Sells 46,137 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-31-24 07:00AM	Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference (GlobeNewswire)
Jan-24-24 12:20AM	Director Jeffrey Albers Sells 10,000 Shares of Kymera Therapeutics Inc (GuruFocus.com)
Jan-17-24 08:00AM	INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors (GlobeNewswire)
Jan-09-24 09:17AM	Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs (GlobeNewswire) +7.80%
09:15AM	Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-05-24 04:03PM	Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering (Investor's Business Daily)
06:00AM	Kymera Therapeutics Announces Pricing of $275 Million Public Offering (GlobeNewswire)
Jan-04-24 04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire) +18.86%
07:00AM	R&D Day Highlights Kymera's Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases (GlobeNewswire)
Jan-02-24 07:00AM	Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 (GlobeNewswire)
Dec-22-23 10:45AM	Kymera Therapeutics Has Doubled in 2 Months, But Is the Upside Sustainable? (TheStreet.com)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-13-23 07:00AM	Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4 (GlobeNewswire) +7.33%
Dec-10-23 09:00PM	Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting (GlobeNewswire)
Dec-08-23 11:13AM	Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474 (Zacks)
Dec-07-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi (GlobeNewswire) +7.20%
Nov-13-23 11:00AM	Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine (GlobeNewswire)
Nov-07-23 09:05AM	BIOTECHNOLOGY VALUE FUND L P Adds to Its Stake in Kymera Therapeutics Inc (GuruFocus.com) +13.61%
Nov-05-23 02:38PM	Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 09:00AM	Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting (GlobeNewswire)
08:43AM	Kymera Therapeutics Inc (KYMR) Announces Q3 2023 Financial Results (GuruFocus.com)
07:00AM	Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-01-23 07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-27-23 07:00AM	Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi (GlobeNewswire)
Oct-26-23 10:02AM	Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know (Zacks)

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chiniara Ellen	Chief Legal Officer	Mar 03 '25	Sale	30.45	2,241	68,239	80,085	Mar 03 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 03 '25	Sale	30.45	1,383	42,113	67,800	Mar 03 06:30 PM
Jacobs Bruce N.	Chief Financial Officer	Mar 03 '25	Sale	30.45	7,035	214,219	201,886	Mar 03 06:30 PM
Gollob Jared	Chief Medical Officer	Mar 03 '25	Sale	30.45	5,740	174,786	120,000	Mar 03 06:30 PM
Gollob Jared	Officer	Mar 03 '25	Proposed Sale	31.35	5,740	179,949		Mar 03 06:00 PM
Chiniara Ellen	Officer	Mar 03 '25	Proposed Sale	31.35	2,241	70,255		Mar 03 06:00 PM
Chadwick Jeremy G	Officer	Mar 03 '25	Proposed Sale	31.35	1,383	43,357		Mar 03 06:00 PM
Jacobs Bruce N.	Officer	Mar 03 '25	Proposed Sale	31.35	7,035	220,547		Mar 03 06:00 PM
Mainolfi Nello	Chief Executive Officer	Jan 10 '25	Option Exercise	2.08	10,000	20,800	659,959	Jan 13 07:00 AM
Jacobs Bruce N.	Chief Financial Officer	Jan 10 '25	Option Exercise	2.08	10,000	20,800	178,921	Jan 13 07:00 AM
Chiniara Ellen	Chief Legal Officer	Jan 06 '25	Sale	41.75	3,129	130,645	54,826	Jan 06 05:00 PM
Chiniara Ellen	Officer	Jan 06 '25	Proposed Sale	41.59	3,129	130,135		Jan 06 04:30 PM
Esposito Pamela	Director	Dec 02 '24	Option Exercise	29.55	2,500	73,875	2,500	Dec 02 07:50 PM
Esposito Pamela	Director	Dec 02 '24	Sale	49.00	2,500	122,500	0	Dec 02 07:50 PM
PAMELA ESPOSITO	Director	Dec 02 '24	Proposed Sale	46.85	2,500	117,125		Dec 02 04:41 PM
Esposito Pamela	Director	Sep 17 '24	Option Exercise	23.86	13,500	322,075	13,500	Sep 17 06:20 PM
Esposito Pamela	Director	Sep 17 '24	Sale	48.28	13,500	651,766	0	Sep 17 06:20 PM
PAMELA ESPOSITO	Director	Sep 17 '24	Proposed Sale	48.48	13,500	654,480		Sep 17 04:40 PM
Albers Jeffrey W.	Director	Aug 26 '24	Option Exercise	10.34	5,000	51,700	5,000	Aug 26 06:31 PM
Albers Jeffrey W.	Director	Aug 26 '24	Sale	49.10	5,000	245,508	0	Aug 26 06:31 PM
JOANNA HOROBIN	Director	Aug 26 '24	Proposed Sale	49.16	12,000	589,896		Aug 26 04:32 PM
JEFFREY ALBERS	Director	Aug 26 '24	Proposed Sale	47.78	5,000	238,900		Aug 26 04:25 PM
BAKER BROS. ADVISORS LP	Director	Aug 20 '24	Buy	46.41	1	46	5,516,986	Aug 22 04:03 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Option Exercise	2.08	23,145	48,142	118,885	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Option Exercise	2.08	16,455	34,226	112,195	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 16 '24	Sale	45.81	23,145	1,060,218	95,470	Jul 16 06:00 PM
Gollob Jared	Chief Medical Officer	Jul 15 '24	Sale	45.15	16,455	742,925	95,740	Jul 16 06:00 PM
Booth Bruce	Director	Jul 09 '24	Sale	38.21	453,960	17,346,919	723,246	Jul 09 05:15 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '24	Option Exercise	5.33	18,773	100,060	649,959	Jul 01 04:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 27 '24	Option Exercise	2.08	25,000	52,000	168,554	Jun 28 08:30 AM
Mainolfi Nello	Chief Executive Officer	Jun 18 '24	Option Exercise	2.08	14,413	29,979	631,186	Jun 20 08:30 AM
Booth Bruce	Director	Jun 12 '24	Sale	35.45	16,740	593,378	803,792	Jun 14 06:01 PM
Booth Bruce	Director	Jun 13 '24	Sale	34.98	10,200	356,796	802,022	Jun 14 06:01 PM
Horobin Joanna	Director	Jun 07 '24	Option Exercise	2.08	8,500	17,680	8,500	Jun 07 06:36 PM
Horobin Joanna	Director	Jun 07 '24	Sale	32.99	8,500	280,400	0	Jun 07 06:36 PM
Chadwick Jeremy G	Chief Operating Officer	May 23 '24	Sale	34.99	2,575	90,105	44,183	May 23 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KYMR

Kymera Therapeutics Inc

Upgrade your FINVIZ experience